CEL Stock Overview
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines.
Celadon Pharmaceuticals Plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.54|
|52 Week High||UK£1.50|
|52 Week Low||UK£0.49|
|1 Month Change||-24.11%|
|3 Month Change||-33.13%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-63.10%|
Recent News & Updates
|CEL||GB Pharmaceuticals||GB Market|
Return vs Industry: Insufficient data to determine how CEL performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CEL performed against the UK Market.
|CEL Average Weekly Movement||4.9%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||5.9%|
|10% most volatile stocks in GB Market||11.0%|
|10% least volatile stocks in GB Market||2.9%|
Stable Share Price: CEL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CEL's weekly volatility (5%) has been stable over the past year.
About the Company
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis.
Celadon Pharmaceuticals Plc Fundamentals Summary
|CEL fundamental statistics|
Is CEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CEL income statement (TTM)|
|Cost of Revenue||UK£23.67k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.19|
|Net Profit Margin||-102,299.72%|
How did CEL perform over the long term?See historical performance and comparison